Menopur (Menotrophin)

Menotropin’s FSH component binds to FSH receptors on granulosa cells, promoting estrogen production and follicle growth. The LH component activates LH receptors on theca cells, supporting androgen synthesis and luteinization. Together they mimic the natural hormonal signals that lead to mature follicle formation and ovulation.

The dose of Menopur is individualized. A prescribing clinician determines the amount and schedule based on the patient’s ovarian reserve, treatment protocol, and response to monitoring. Dosing is adjusted according to ultrasound and hormone level assessments during the treatment cycle.

Menopur is intended for use before pregnancy to achieve ovulation or oocyte retrieval. Once pregnancy is confirmed, treatment is stopped. Safety data for use during pregnancy or breastfeeding are limited, and the product is generally not recommended in these periods.

To request Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Menopur provides both FSH and LH activity in a single preparation, whereas some alternatives supply only FSH (e.g., recombinant FSH) and require separate LH supplementation. This combined profile can simplify dosing and may be advantageous in protocols that need both hormones for optimal follicular response.

Menopur should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, use the solution according to the manufacturer’s instructions and discard any unused portion after the recommended time.

Menopur is supplied as a powder for solution for injection. After reconstitution with the appropriate diluent, it is administered subcutaneously, typically in the abdominal wall or thigh, according to the dosing schedule prescribed by the treating physician.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and thromboembolic events, as well as the possibility of multiple pregnancies and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for these complications.

Menopur is contraindicated in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, or known hypersensitivity to menotropin. It should also be avoided in patients at high risk for severe OHSS or those with conditions that make pregnancy unsafe.